A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors
- PMID: 27080977
- PMCID: PMC5084892
- DOI: 10.1681/ASN.2015091065
A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors
Abstract
Accurate identification of risk factors for calcific uremic arteriolopathy (CUA) is necessary to develop preventive strategies for this morbid disease. We investigated whether baseline factors recorded at hemodialysis initiation would identify patients at risk for future CUA in a matched case-control study using data from a large dialysis organization. Hemodialysis patients with newly diagnosed CUA (n=1030) between January 1, 2010, and December 31, 2014, were matched by age, sex, and race in a 1:2 ratio to hemodialysis patients without CUA (n=2060). Mean ages for patients and controls were 54 and 55 years, respectively; 67% of participants were women and 49% were white. Median duration between hemodialysis initiation and subsequent CUA development was 925 days (interquartile range, 273-2185 days). In multivariable conditional logistic regression analyses, diabetes mellitus; higher body mass index; higher levels of serum calcium, phosphorous, and parathyroid hormone; and nutritional vitamin D, cinacalcet, and warfarin treatments were associated with increased odds of subsequent CUA development. Compared with patients with diabetes receiving no insulin injections, those receiving insulin injections had a dose-response increase in the odds of CUA involving lower abdomen and/or upper thigh areas (odds ratio, 1.49; 95% confidence interval, 1.03 to 2.51 for one or two injections per day; odds ratio, 1.88; 95% confidence interval, 1.30 to 3.43 for 3 injections per day; odds ratio, 3.74; 95% confidence interval, 2.28 to 6.25 for more than three injections per day), suggesting a dose-effect relationship between recurrent skin trauma and CUA risk. The presence of risk factors months to years before CUA development observed in this study will direct the design of preventive strategies and inform CUA pathobiology.
Keywords: clinical epidemiology; diabetes mellitus; end stage kidney disease; hemodialysis; obesity; vascular calcification.
Copyright © 2016 by the American Society of Nephrology.
Figures
Comment in
-
Calcific Uremic Arteriolopathy Revisited.J Am Soc Nephrol. 2016 Nov;27(11):3233-3235. doi: 10.1681/ASN.2016040480. Epub 2016 May 25. J Am Soc Nephrol. 2016. PMID: 27225039 Free PMC article. No abstract available.
References
-
- Hayden MR, Kolb LG, Khanna R: Calciphylaxis and the cardiometabolic syndrome. J Cardiometab Syndr 1: 76–79, 2006 - PubMed
-
- Angelis M, Wong LL, Myers SA, Wong LM: Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122: 1083–1089, discussion 1089–1090, 1997 - PubMed
-
- Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y Japanese Calciphylaxis Study Group : A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27: 1580–1584, 2012 - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
